Lilly's New GLP-1 Pill Outperforms Competitors in Weight Loss and Diabetes Trials
TL;DR Summary
A new oral GLP-1 agonist, orforglipron, has shown promising results in a large trial, helping obese patients lose up to 11% of their body weight over 72 weeks, offering a potentially more accessible alternative to injectable treatments, with significant improvements in cardiometabolic health markers.
- New Pill for Obesity Delivers Major Weight Reduction Without Injections SciTechDaily
- Eli Lilly’s Diabetes Drug Tops Novo Nordisk’s Oral Pill in Trial The Wall Street Journal
- Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial Eli Lilly and Company
- Lilly gets a boost from new weight-loss pill data as it weighs speedier approval in US Reuters
- Lilly’s GLP-1 Pill Beats Older Novo Diabetes Drug in Head-to-Head Trial Bloomberg.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 5 min read
Condensed
95%
852 → 44 words
Want the full story? Read the original article
Read on SciTechDaily